Expenses and EPS performance in H1 2018
In H1 2018, Antares Pharma (ATRS) reported a loss per share of $0.07, which was higher by $0.02 on a year-over-year (or YoY) basis. Losses increased due to rising operating expenses and an unfavorable shift in product mix.
The company reported operating expenses of $22.25 million in H1 2018, a YoY rise of 6%, which is mainly attributable to a 12% YoY rise in research and development expenses associated with pipeline products. The company also spent a significant amount in preparation for the commercial launch of the Xyosted injection in H1 2018.
Wall Street analysts expect Antares Pharma to report a loss per share of $0.11 in fiscal 2018, which is a YoY increase of 3.64%. The company is, however, expected to become profitable and report EPS of $0.05 and $0.25 in fiscal 2019 and fiscal 2020, respectively.
Antares Pharma is a leading player in the injectable drug delivery segment and plans to leverage its QuickShot platform to develop multiple drug-device combinations similar to Xyosted and Makena auto injectors.
As per the company’s investor presentation, Antares Pharma aims to launch the Xyosted auto injector in the US market in Q4 2018. The company is also focused on boosting the uptake of the Makena auto injector in the US market in H2 2018.
On August 6, Antares Pharma released a press release announcing its partnership with Pfizer (PFE) to develop a combination drug-device product, a rescue pen using the former’s QuickShot auto injector technology and the latter’s undisclosed drug. The press release explains the role of the companies in this partnership. Pfizer is responsible for paying to develop the product, secure FDA approval, and commercialize the product. Antares Pharma will be supplying finished products to Pfizer in exchange of cost plus margin reimbursement. Antares Pharma will also be earning royalties from the net sales of the combination rescue pen.
In the next article, we’ll discuss the Makena auto injector in greater detail.